| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 12/25/2001 | US6333341 Tumor necrosis factor, antiinflammatory agents and analgesics |
| 12/25/2001 | US6333339 3-Benzylpiperidine |
| 12/25/2001 | US6333337 Potassium channel inhibitors |
| 12/25/2001 | US6333311 Has inflammatory and immune response functions such as regulation of monocyte colony stimulating factor synthesis, regulation of interleukin synthesis, activation of natural killer cell activity, inhibition of metastasis |
| 12/25/2001 | US6333020 Methods for treating AVM's using radio active compositions |
| 12/25/2001 | CA2139385C Products containing g-csf and tnf binding protein |
| 12/25/2001 | CA2018714C Hypothalamic polypeptides with adenylate cyclase stimulating activity |
| 12/21/2001 | CA2351129A1 Novel substituted nitrocatechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them |
| 12/21/2001 | CA2351125A1 Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them |
| 12/20/2001 | WO2001096598A2 cDNA FOR HUMAN METHYLENETETRAHYDROFOLATE REDUCTASE AND USES THEREOF |
| 12/20/2001 | WO2001096567A1 Novel g protein-coupled receptor protein and dna thereof |
| 12/20/2001 | WO2001096565A2 Binding agents: chimeric ligand/receptor proteins |
| 12/20/2001 | WO2001096563A1 Scramblase 2 |
| 12/20/2001 | WO2001096553A1 Novel g protein-coupled receptor protein and dna thereof |
| 12/20/2001 | WO2001096547A2 Human kinases |
| 12/20/2001 | WO2001096546A2 Protein phosphatases |
| 12/20/2001 | WO2001096397A2 Cd154 variants and uses thereof |
| 12/20/2001 | WO2001096347A1 HMG-CoA REDUCTASE INHIBITORS AND METHOD |
| 12/20/2001 | WO2001096345A1 Tetrapyrroles |
| 12/20/2001 | WO2001096343A1 Substituted metal-phthalocyanines, their preparation and the use thereof |
| 12/20/2001 | WO2001096337A1 4-oxoimidazolidine-2-spiro-nitrogenous heterocycle compounds |
| 12/20/2001 | WO2001096336A2 6,5-fused bicyclic heterocycles |
| 12/20/2001 | WO2001096335A1 Imidazo[1,2-a]pyridine ether compounds as ion channel modulators |
| 12/20/2001 | WO2001096334A2 Heteroarylalkanoic acids as integrin receptor antagonists |
| 12/20/2001 | WO2001096331A1 Lactam inhibitors of factor xa and method |
| 12/20/2001 | WO2001096330A2 Thrombin receptor antagonists |
| 12/20/2001 | WO2001096327A1 BIOISOSTERIC BENZAMIDE DERIVATIVES AND THEIR USE AS APoB-100 SECRETION INHIBITORS |
| 12/20/2001 | WO2001096323A1 Serine protease inhibitors |
| 12/20/2001 | WO2001096312A1 Integrin ligands |
| 12/20/2001 | WO2001096311A2 Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases |
| 12/20/2001 | WO2001096310A1 Dihydrostilbene alkanoic acid derivatives useful as vitronectin antagonists |
| 12/20/2001 | WO2001096309A1 Hydroxyformamidine derivatives and medicines containing the same |
| 12/20/2001 | WO2001096308A1 1,2-dihydropyridine compounds, process for preparation of the same and use thereof |
| 12/20/2001 | WO2001096307A2 Cycloalkyl alkanoic acids as integrin receptor antagonists |
| 12/20/2001 | WO2001096305A1 Serine protease inhibitors |
| 12/20/2001 | WO2001096302A1 Piperidines for use as orexin receptor antagonists |
| 12/20/2001 | WO2001096299A2 Indole derivatives and their use as 15-lipoxygenase inhibitors |
| 12/20/2001 | WO2001096298A2 1,2,4-trisubstituted benzenes as inhibitors of 15-lipoxygenase |
| 12/20/2001 | WO2001096296A1 Serine protease inhibitors |
| 12/20/2001 | WO2001096285A1 Beta-amino acid nitrile derivatives |
| 12/20/2001 | WO2001095946A2 Combination product for carrying out a cytotoxic treatment in a mammal |
| 12/20/2001 | WO2001095937A2 Phytoestrogenic isoflavone compositions |
| 12/20/2001 | WO2001095932A1 A COMBINATION PRODUCT COMPRISING MELAGATRAN AND A FACTOR VIIa INHIBITOR |
| 12/20/2001 | WO2001095930A1 Method of photoreduction of hemoglobin vesicles |
| 12/20/2001 | WO2001095906A1 Treatment and prevention of cardiac insulin resistance associated conditions |
| 12/20/2001 | WO2001095895A2 Methods of potentiating organic nitrates having vasodilating activity and formulations for the same |
| 12/20/2001 | WO2001095893A1 Use of an epoxy-steroidal aldosterone antagonist for the treatment or prophylaxis of aldosterone-mediated pathogenic effects |
| 12/20/2001 | WO2001095892A1 Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects |
| 12/20/2001 | WO2001095859A2 Novel heterocyclic analogs of diphenylethylene compounds |
| 12/20/2001 | WO2001095831A2 Cardiac disease treatment and device |
| 12/20/2001 | WO2001095785A2 Modulation of immune response and methods based thereon |
| 12/20/2001 | WO2001066550A3 Compounds for pdt |
| 12/20/2001 | WO2001062245A3 Bilirubin or biliverdin degradation fragments |
| 12/20/2001 | WO2001059128A3 Novel elongase gene and method for producing multiple-unsaturated fatty acids |
| 12/20/2001 | WO2001058896A8 Benzoxazole derivatives as tnf and pde iv inhibitors |
| 12/20/2001 | WO2001049689A3 NOVEL SUBSTITUTED PYRAZOLO[4,3-e]DIAZEPINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, USE AS MEDICINAL PRODUCTS AND PROCESSES FOR PREPARING THEM |
| 12/20/2001 | WO2001031016A3 Processed human chemokines phc-1 and phc-2 |
| 12/20/2001 | WO2000024452A9 Systems and compounds for drug delivery to interstitial regions of the myocardium |
| 12/20/2001 | WO1997049394A3 Sold oral dosage forms of valsartan |
| 12/20/2001 | US20010053853 Alkanoic acid derivative; integrin receptor antagonist |
| 12/20/2001 | US20010053844 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 12/20/2001 | US20010053790 Mothod and composition for treatment of ischemic neuronal reperfusion injury |
| 12/20/2001 | US20010053788 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity |
| 12/20/2001 | US20010053778 Pharmaceutical compositions of glycogen phosphorylase inhibitors |
| 12/20/2001 | US20010053774 Non-steroidal ligands for the estrogen receptor |
| 12/20/2001 | US20010053765 Methods and compositions for the selective regulation of chorionic prostanoids |
| 12/20/2001 | US20010053764 Interleukin-1 inhibitors in the treatment of diseases |
| 12/20/2001 | US20010053763 Method and composition for modulating an immune response |
| 12/20/2001 | US20010053760 Treatment of infarcts |
| 12/20/2001 | US20010053357 Peptide having an amino acid sequence corresponding to an amino acid sequence of a V-domain of a receptor for advanced glycation endproduct. |
| 12/20/2001 | US20010053351 Inhibition of GSK-3 beta |
| 12/20/2001 | DE10037272A1 Identifying agents for treating cardiovascular disease, comprises determining the ability of potential agents to modify interaction between beta3 endonexin and beta3 integrin |
| 12/20/2001 | DE10029015A1 Coagulation Factor Xa inhibitor, useful for treatment, prophylaxis or diagnosis of thromboembolic disease, comprising acylated 3- or 4-amidino-benzylamine derivative |
| 12/20/2001 | DE10028402A1 New pyridinylamino-alkanoyl-glycyl-beta-alanine derivatives, are integrin inhibitors useful for treating, e.g. thrombosis, cardiac infarction, coronary heart disease, inflammation, tumors, osteoporosis or restenosis |
| 12/20/2001 | DE10027383A1 Nukleinsäure-Molekül umfassend eine für ein Chemokin, einen Neuropeptid-Präkursor oder mindestens ein Neuropeptid kodierende Nukleinsäuresequenz Nucleic acid molecule comprising a sequence coding for a chemokine, a neuropeptide precursor or at least one neuropeptide nucleic acid sequence |
| 12/20/2001 | DE10026666A1 Verwendung von Hyaluronidase zur Prophylaxe und Behandlung von Herz-Kreislauf-Erkrankungen Use of hyaluronidase for the prophylaxis and treatment of cardiovascular diseases |
| 12/20/2001 | CA2436116A1 Treatment and prevention of cardiac insulin resistance associated conditions |
| 12/20/2001 | CA2415369A1 Thromboxane receptor antagonist containing formulations for potentiating organic nitrates having vasodilating activity |
| 12/20/2001 | CA2412979A1 Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases |
| 12/20/2001 | CA2412842A1 Combination product for carrying out a cytotoxic treatment in a mammal |
| 12/20/2001 | CA2412665A1 Scramblase 2 |
| 12/20/2001 | CA2412632A1 Hmg-coa reductase inhibitors and method |
| 12/20/2001 | CA2412623A1 Tetrapyrroles |
| 12/20/2001 | CA2412462A1 6,5-fused bicyclic heterocycles |
| 12/20/2001 | CA2412216A1 Lactam inhibitors of factor xa and method |
| 12/20/2001 | CA2411805A1 Serine protease inhibitors |
| 12/20/2001 | CA2411798A1 Serine protease inhibitors |
| 12/20/2001 | CA2411495A1 1,2,4-trisubstituted benzenes as inhibitors of 15-lipoxygenase |
| 12/20/2001 | CA2411472A1 Cd154 variants |
| 12/20/2001 | CA2411116A1 Indole derivatives and their use as 15-lipoxygenase inhibitors |
| 12/20/2001 | CA2410610A1 Human kinases |
| 12/20/2001 | CA2410228A1 A combination product comprising melagatran and a factor viia inhibitor |
| 12/20/2001 | CA2410171A1 Novel heterocyclic analogs of diphenylethylene compounds and uses thereof |
| 12/20/2001 | CA2409315A1 Protein phosphatases |
| 12/20/2001 | CA2407699A1 Use of an aldosterone antagonist for the treatment or prophylaxis of aldosterone-mediated pathogenic effects |
| 12/19/2001 | EP1164145A2 Non-anticoagulant desulfated heparins as medicaments |
| 12/19/2001 | EP1164135A1 Substituted metal-phthalocyanines, their preparation and the use thereof |
| 12/19/2001 | EP1163908A1 Water-soluble complex of an extract of Ginkgo Bilboa, process for the preparation thereof and composition comprising the same |
| 12/19/2001 | EP1163904A1 Composition for the prevention of smooth muscle diseases comprising ascorbate, arginine and magnesium |
| 12/19/2001 | EP1163523A1 Method for detecting predisposition to a venous thromboembolic disease |